Characteristic | |
Sex (M:F) (n) | 17:5 |
Status (dead/alive) (n) | 2:20 |
Age at biopsy (y) | 60.2 (6.2) (44–69) |
Dust exposure (yes/no) (n) | 9:13 |
Smoker (yes/no) (n) | 12:10 |
Smoking (pack-years) | 23.3 (19.1) (0.45–64) |
Follow-up (months) (median (range)) | 9 (6–11) |
Pathological features | |
Fibroblastic foci score (%) | |
1 | 4.6 |
2 | 40.9 |
3 | 13.6 |
4 | 22.7 |
5 | 4.6 |
6 | 13.6 |
Fibroblastic foci (AFF %) (median (range)) | 8.4 (4.3–21.8) |
Fibrosis extension (AFib %) | 35.6 (7.4) (22–51.8) |
Inflammation score (%) | |
1 | 53.8 |
2 | 38.5 |
3 | 7.7 |
Inflammation (AIC %) | 3.0 (1.4) (1.2–6.6) |
Spirometry at time of diagnosis | |
Tlco (% predicted) | 53.7 (12.7) (23–77) |
FEV1 (% predicted) | 72.9 (15.7) (42–109) |
FVC (% predicted) | 69.5 (13.6) (49–97) |
VC (% predicted) | 71.1 (12.7) (47–94) |
TLC (% predicted) | 67.1 (12.9) (48–91) |
RV (% predicted) | 67.7 (25.5) (31–125) |
Values are mean (SD) (range) unless otherwise stated. For normally distributed quantitative variables, values are mean (SD) (range); for not normally distributed quantitative variables, median range (IQR) are shown; for categorical variables, percentage distributions are shown.
AFF, fibroblastic foci area; AFib, fibrotic area; AIC, inflammatory cells area; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; Tlco, carbon monoxide transfer factor; VC, vital capacity.